Skip to main content
GELS
NASDAQ Life Sciences

Gelteq Ltd Receives Nasdaq Delisting Notice for Sub-$1.00 Share Price

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
9
Price
$0.71
Mkt Cap
$7.607M
52W Low
$0.64
52W High
$4.11
Market data snapshot near publication time

Summary

Gelteq Ltd has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement, initiating a 180-day period to regain compliance and avoid potential delisting.


Key Events

  • Nasdaq Minimum Bid Price Deficiency

    Gelteq Ltd received a letter from Nasdaq for failing to meet the minimum $1.00 bid price requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).

  • 180-Day Compliance Period Initiated

    The company has a compliance period of 180 calendar days, until September 14, 2026, to regain compliance by having its ordinary shares close at or above $1.00 for at least ten consecutive business days.

  • Potential for Additional Grace Period

    If compliance is not met by the deadline, the company may be eligible for an additional 180-day grace period, provided it meets other listing standards and intends to cure the deficiency, potentially through a reverse stock split.

  • Shares Continue to Trade

    The Nasdaq notification does not result in immediate delisting, and the company's shares will continue to trade uninterrupted under the symbol "GELS".


Analysis

This Nasdaq notification signals a critical risk for Gelteq Ltd, as maintaining a listing on a major exchange is vital for investor visibility and liquidity, particularly for a micro-cap company. Failure to regain compliance by September 14, 2026, could lead to delisting, potentially forcing the company to consider a reverse stock split or move to an over-the-counter market. Such a move often results in reduced trading volume and investor interest, further complicating capital-raising efforts. Investors should closely monitor the company's stock price performance and any strategic actions announced to address this deficiency.

At the time of this filing, GELS was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6M. The 52-week trading range was $0.64 to $4.11. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GELS - Latest Insights

GELS
Jun 12, 2026, 12:30 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.9799
Real-time Price: $0.9699 info
Change: -$0.010 (-1%) info
Market Cap: $10.604M info
GELS
Jun 04, 2026, 9:08 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.550
Real-time Price: $0.9699 info
Change: +$0.4199 (+76%) info
Market Cap: $10.604M info
GELS
Jun 02, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.484118
Real-time Price: $0.9699 info
Change: +$0.485782 (+100%) info
Market Cap: $10.604M info
GELS
May 26, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.422
Real-time Price: $0.9699 info
Change: +$0.5479 (+130%) info
Market Cap: $10.604M info
GELS
May 20, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.391
Real-time Price: $0.9699 info
Change: +$0.5789 (+148%) info
Market Cap: $10.604M info
GELS
May 12, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.391
Real-time Price: $0.9699 info
Change: +$0.5789 (+148%) info
Market Cap: $10.604M info
GELS
Mar 24, 2026, 8:15 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.7102
Real-time Price: $0.9699 info
Change: +$0.2597 (+37%) info
Market Cap: $10.604M info